The pharmacokinetics of propafenone and 5-OH-propafenone and their relationship with the antiarrhythmic action and side effects have been studied in 10 patients with stable, frequent, premature ventricular beats (224–928 premature ventricular complexes/h). Observations were made after a single dose of propafenone 300 mg p.o., and after 1 and 3 months (only 5 out of 10 patients) of therapy with 300 mg t.d.s.
After 1 month of treatment the plasma elimination half-life of propafenone (6.7 h) was almost twice as long as after a single dose (3.5 h), and the area under the plasma propafenone concentration-time curve (7620 ng·ml−1·h) was significantly larger than after single dose (3522 ng·ml−1·h); this was also true for the metabolite. The ratio of the AUCs of 5-OH-propafenone and propafenone decreased from the single dose (0.63) to 1 month (0.32). These variables remained stable up to 3 months.
Eight patients had ≧75% reduction of premature ventricular complexes after 3 days of therapy, and in 7 they were completely suppressed; the response was maintained over 1 to 3 months. Side effects were minor and in no case had the drug to be withdrawn or the dose reduced.
Thus, the kinetics of propafenone were time-dependent. Its active metabolite did not accumulate greatly during chronic treatment. The lasting antiarrhythmic effect observed in some patients suggests a b.d.s. regimen instead of t.d.s. dosing in selected patients.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Ledda F, Mantelli L, Manzini S, Amerini S, Mugelli A (1981) Electrophysiological and antiarrhythmic properties of propafenon in isolated cardiac preparations. J Cardiovasc Pharmacol 3: 1162–1173
McLeod AA, Stiles GL, Shand DG (1984) Demonstration of beta-adrenoceptor blockade by propafenone hydrochloride: Clinical pharmacologic, radioligand binding and adenylate cyclase activation studies. J Pharmacol Exp Ther 228: 461–466
Connolly SJ, Kates RE, Lebsack CS, Echt DS, Mason JW, Winkle RA (1983) Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. Am J Cardiol 52: 1208–1213
Coumel P, Leclercq J-F, Assayag P (1984) European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. Am J Cardiol 54: 60D-66D
Salerno DM, Granrud G, Sharkey P, Asinger R, Hodges M (1984) A controlled trial of propafenone for treatment of frequent and repetitive ventricular premature complexes. Am J Cardiol 53: 77–83
Naccarella F, Bracchetti D, Palmieri M, Marchesini B, Ambrosioni E (1984) Propafenone for refractory ventricular arrhythmias: Correlation with drug plasma levels during long-term treatment. Am J Cardiol 54: 1008–1014
Heger JJ, Hubbard J, Zipes DP, Miles WM, Prystowsky EN (1984) Propafenone treatment of recurrent ventricular tachycardia: comparison of continuous electrocardiographic recording and electrophysiologic study in predicting drug efficacy. Am J Cardiol 54: 40D-44D
Breithardt G, Borggrefe M, Wiebringhaus E, Seipel L (1984) Effect of propafenone in the Wolff-Parkinson-White syndrome: Electrophysiologic findings and long-term follow-up. Am J Cardiol 54: 29D-39D
Podrid PJ, Lown B (1984) Propafenone: A new agent for ventricular arrhythmia. J Am Coll Cardiol 4: 117–125
Dinh H, Murphy ML, Baker BJ, deSoyza N, Franciosa JA (1985) Efficacy of propafenone compared with quinidine in chronic ventricular arrhythmias. Am J Cardiol 55: 1520–1524
Hammill SC, Sorenson PBS, Wood DL, Sugure DD, Osborn MJ, Gersh BJ, Holmes DR (1986) Propafenone for the treatment of refractory complex ventricular ectopic activity. Mayo Clin Proc 61: 98–103
Hollmann M, Brode E, Hotz D, Kaumeier S, Kehrhahn OH (1983) Investigations on the pharmacokinetics of propafenone in man. Arzneimittelforschung 33: 763–770
Connolly SJ, Kates RE, Lesback CS, Harrison DC, Winkle RA (1983) Clinical pharmacology of propafenone. Circulation 68: 589–596
Connolly S, Lesback C, Winkle RA, Harrison DC, Kates RE (1984) Propafenone disposition kinetics in cardiac arrhythmia. Clin Pharmacol Ther 36: 163–168
Kates RE, Yee YG, Winkle RA (1985) Metabolite cumulation during chronic propafenone dosing in arrhythmia. Clin Pharmacol Ther 37: 610–614
Philipsborn G von, Gries J, Hofmann HP, Kreiskott H, Kretzschmar R, Muller CD, Raschack M, Teschendorf HJ (1984) Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone. Arzneimittelforschung 34: 1489–1497
Thompson KA, Siddoway LA, Woosley RL (1985) Potent dose-dependent electrophysiologic effects of the major metabolite of propafenone. Circulation 72 [Suppl 3], abstract 932
Latini R, Sica A, Marchi S, Chen ZM, Gavinelli M, Benfenati E (1988) HPLC separation and mass spectrometry identification of propafenone, 5-hydroxy-propafenone and N-depropyl-propafenone. J Chromatogr 424: 211–214
Rocchetti M, Recchia M (1982) SPBS: Statistical programs for biological sciences. Mini computer software for applying routine biostatistical methods. Comput Programs Biomed 14: 7–20
Rowland M (1978) Drug administration and regimens. In: Melmon KL, Morrelli HF (eds) Clinical pharmacology. Basic principles in therapeutics. Macmillam, New York, pp 25–70
Hege HG, Hollmann M, Kaumeier S, Lietz H (1984) The metabolic fate of2H-labelled propafenone in man. Eur J Drug Metab Pharmacokinet 9: 41–55
Siddoway LA, Roden DM, Woosley RL (1984) Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations. Am J Cardiol 54: 9D-12D
About this article
Cite this article
Giani, P., Landolina, M., Giudici, V. et al. Pharmacokinetics and pharmacodynamics of propafenone during acute and chronic administration. Eur J Clin Pharmacol 34, 187–194 (1988). https://doi.org/10.1007/BF00614557
- antiarrhythmic effect
- chronic treatment